These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 30951756)
1. Timosaponin AIII, a steroidal saponin, exhibits anti-tumor effect on taxol-resistant cells in vitro and in vivo. Song XY; Han FY; Chen JJ; Wang W; Zhang Y; Yao GD; Song SJ Steroids; 2019 Jun; 146():57-64. PubMed ID: 30951756 [TBL] [Abstract][Full Text] [Related]
2. Timosaponin A‑III induces autophagy of T‑cell acute lymphoblastic leukemia Jurkat cells via inhibition of the PI3K/Akt/mTOR pathway. Wang H; Dong R; Fan WW; Zheng XC; Li AM; Wang WD Oncol Rep; 2019 May; 41(5):2937-2944. PubMed ID: 30896824 [TBL] [Abstract][Full Text] [Related]
3. Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway. Chen JR; Jia XH; Wang H; Yi YJ; Wang JY; Li YJ Int J Oncol; 2016 May; 48(5):2063-70. PubMed ID: 26984633 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of autophagy enhances timosaponin AIII-induced lung cancer cell apoptosis and anti-tumor effect in vitro and in vivo. Liu J; Deng X; Sun X; Dong J; Huang J Life Sci; 2020 Sep; 257():118040. PubMed ID: 32622943 [TBL] [Abstract][Full Text] [Related]
5. Timosaponin AIII is preferentially cytotoxic to tumor cells through inhibition of mTOR and induction of ER stress. King FW; Fong S; Griffin C; Shoemaker M; Staub R; Zhang YL; Cohen I; Shtivelman E PLoS One; 2009 Sep; 4(9):e7283. PubMed ID: 19789631 [TBL] [Abstract][Full Text] [Related]
6. Antibody-modified liposomes for tumor-targeting delivery of timosaponin AIII. Lu L; Ding Y; Zhang Y; Ho RJ; Zhao Y; Zhang T; Guo C Int J Nanomedicine; 2018; 13():1927-1944. PubMed ID: 29636610 [TBL] [Abstract][Full Text] [Related]
7. Timosaponin AIII mediates caspase activation and induces apoptosis through JNK1/2 pathway in human promyelocytic leukemia cells. Huang HL; Chiang WL; Hsiao PC; Chien MH; Chen HY; Weng WC; Hsieh MJ; Yang SF Tumour Biol; 2015 May; 36(5):3489-97. PubMed ID: 25542232 [TBL] [Abstract][Full Text] [Related]
8. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway. Zheng R; Jiang H; Li J; Liu X; Xu H Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061 [TBL] [Abstract][Full Text] [Related]
9. A novel mechanism of XIAP degradation induced by timosaponin AIII in hepatocellular carcinoma. Wang N; Feng Y; Zhu M; Siu FM; Ng KM; Che CM Biochim Biophys Acta; 2013 Dec; 1833(12):2890-2899. PubMed ID: 23906794 [TBL] [Abstract][Full Text] [Related]
10. Timosaponin AIII: A novel potential anti-tumor compound from Anemarrhena asphodeloides. Han FY; Song XY; Chen JJ; Yao GD; Song SJ Steroids; 2018 Dec; 140():125-130. PubMed ID: 30296545 [TBL] [Abstract][Full Text] [Related]
11. Timosaponin AIII induces apoptosis and autophagy in human melanoma A375-S2 cells. Wang Y; Xu L; Lou LL; Song SJ; Yao GD; Ge MY; Hayashi T; Tashiro SI; Onodera S; Ikejima T Arch Pharm Res; 2017 Jan; 40(1):69-78. PubMed ID: 27271334 [TBL] [Abstract][Full Text] [Related]
12. Antiangiogenesis effect of timosaponin AIII on HUVECs in vitro and zebrafish embryos in vivo. Zhou ZY; Zhao WR; Xiao Y; Zhou XM; Huang C; Shi WT; Zhang J; Ye Q; Chen XL; Tang JY Acta Pharmacol Sin; 2020 Feb; 41(2):260-269. PubMed ID: 31515528 [TBL] [Abstract][Full Text] [Related]
13. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway. Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144 [TBL] [Abstract][Full Text] [Related]
14. Timosaponin AIII inhibits migration and invasion of A549 human non-small-cell lung cancer cells via attenuations of MMP-2 and MMP-9 by inhibitions of ERK1/2, Src/FAK and β-catenin signaling pathways. Jung O; Lee J; Lee YJ; Yun JM; Son YJ; Cho JY; Ryou C; Lee SY Bioorg Med Chem Lett; 2016 Aug; 26(16):3963-7. PubMed ID: 27422337 [TBL] [Abstract][Full Text] [Related]
15. Delicaflavone induces ROS-mediated apoptosis and inhibits PI3K/AKT/mTOR and Ras/MEK/Erk signaling pathways in colorectal cancer cells. Yao W; Lin Z; Shi P; Chen B; Wang G; Huang J; Sui Y; Liu Q; Li S; Lin X; Liu Q; Yao H Biochem Pharmacol; 2020 Jan; 171():113680. PubMed ID: 31669234 [TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727 [TBL] [Abstract][Full Text] [Related]
17. Zeylenone, a naturally occurring cyclohexene oxide, inhibits proliferation and induces apoptosis in cervical carcinoma cells via PI3K/AKT/mTOR and MAPK/ERK pathways. Zhang L; Huo X; Liao Y; Yang F; Gao L; Cao L Sci Rep; 2017 May; 7(1):1669. PubMed ID: 28490807 [TBL] [Abstract][Full Text] [Related]
18. A Ferulic Acid Derivative FXS-3 Inhibits Proliferation and Metastasis of Human Lung Cancer A549 Cells via Positive JNK Signaling Pathway and Negative ERK/p38, AKT/mTOR and MEK/ERK Signaling Pathways. Yue SJ; Zhang PX; Zhu Y; Li NG; Chen YY; Li JJ; Zhang S; Jin RY; Yan H; Shi XQ; Tang YP; Duan JA Molecules; 2019 Jun; 24(11):. PubMed ID: 31181779 [TBL] [Abstract][Full Text] [Related]
19. Apoptosis and G2/M cell cycle arrest induced by a timosaponin A3 from Anemarrhena asphodeloides Bunge on AsPC-1 pancreatic cancer cells. Kim Y; Kim KH; Lee IS; Park JY; Na YC; Chung WS; Jang HJ Phytomedicine; 2019 Mar; 56():48-56. PubMed ID: 30668353 [TBL] [Abstract][Full Text] [Related]
20. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways. Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]